Search results for "Cholesterol absorption"

showing 10 items of 15 documents

First international descriptive and interventional survey for cholesterol and non-cholesterol sterol determination by gas- and liquid-chromatography–…

2019

International audience; Serum concentrations of lathosterol, the plant sterols campesterol and sitosterol and the cholesterol metabolite 5alpha-cholestanol are widely used as surrogate markers of cholesterol synthesis and absorption, respectively. Increasing numbers of laboratories utilize a broad spectrum of well-established and recently developed methods for the determination of cholesterol and non-cholesterol sterols (NCS). In order to evaluate the quality of these measurements and to identify possible sources of analytical errors our group initiated the first international survey for cholesterol and NCS. The cholesterol and NCS survey was structured as a two-part survey which took place…

0301 basic medicineEndocrinology Diabetes and MetabolismClinical BiochemistryBiochemistryCholesterol balancechemistry.chemical_compound0302 clinical medicineEndocrinologySurveys and QuestionnairesPhytosterolABSORPTIONMedicineCholesterol absorptionPRECURSORSNormal laboratoryPhytosterols[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismSERUM PLANT STEROLSSitosterol3. Good healthCholestanolCholesterolAtherosclerosi030220 oncology & carcinogenesisCholesterol synthesisMolecular Medicinelipids (amino acids peptides and proteins)HumanCholesterol synthesisChromatography GasCholesterol synthesiCampesterolatherosclerosis; cholesterol absorption; cholesterol balance; cholesterol synthesis; phytosterols; surrogate markerLathosterolDeuterium labelledArticle03 medical and health sciencesHumansMolecular BiologyChromatographybusiness.industryCholesterolCell BiologyAtherosclerosisSitosterolsSterol030104 developmental biologychemistryChromatography Ga3121 General medicine internal medicine and other clinical medicine1182 Biochemistry cell and molecular biologyGas chromatographySurrogate markerbusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionChromatography Liquid
researchProduct

Low intestinal cholesterol absorption is associated with a reduced efficacy of phytosterol esters as hypolipemic agents in patients with metabolic sy…

2010

Summary Background & aims Phytosterols (PS) lower LDLc, but their effect on metabolic syndrome (MetS) remains unknown. We evaluated whether low-fat milk enriched with PS improves cardiovascular risk factors in these patients. Methods A randomised parallel trial employing 24 moderate-hypercholesterolaemic MetS patients and consisting of two 3-month intervention phases. After a 3-month healthy diet, patients were divided into two intervention groups: diet (n = 10) and diet + PS (n = 14) (2 g/day). A control group of 24 moderate-hypercholesterolaemic patients without MetS (matched in age and BMI) underwent the same procedure. Results Neither dietary intervention nor enrichment of PS induced an…

AdultMalemedicine.medical_specialtyApolipoprotein BHomocysteineLipoproteinsHypercholesterolemiaPopulationCritical Care and Intensive Care MedicineSeverity of Illness IndexCholesterol Dietarychemistry.chemical_compoundRisk FactorsInternal medicinemedicineHumanseducationHypolipidemic AgentsMetabolic Syndromeeducation.field_of_studyNutrition and Dieteticsmedicine.diagnostic_testbiologybusiness.industryAnticholesteremic AgentsPhytosterolsMiddle Agedmedicine.diseaseSitosterolsCholesterolEndocrinologyIntestinal AbsorptionchemistryCardiovascular DiseasesSpainDietary SupplementsIntestinal cholesterol absorptionbiology.proteinFemaleMetabolic syndromebusinessLipid profileBody mass indexLipoproteinClinical Nutrition
researchProduct

NPC1L1 and ABCG5/8 induction explain synergistic fecal cholesterol excretion in ob/ob mice co-treated with PPAR-α and LXR agonists

2020

Reverse cholesterol transport (RCT) and transintestinal cholesterol efflux (TICE) are two important pathways for body cholesterol elimination. We studied these pathways in an animal model of diabetes and obesity (ob/ob) where HDL function is compromised as a result of hyperglycemia, low-grade inflammation and oxidative stress. Co-treatment of ob/ob mice with PPAR-α (fenofibrate) and LXR (T0901317) agonists increased fecal cholesterol by 12-fold; PPAR-α and LXR agonists individually showed 2.6- and 4.0-fold fecal cholesterol excretion, respectively. We investigated the mechanism of synergistic efficacy of PPAR-α and LXR agonists in fecal cholesterol excretion. LXR agonist and the combination…

Male0301 basic medicinemedicine.medical_specialtyHydrocarbons FluorinatedHDLLipoproteinsClinical BiochemistryMice ObeseABCA1NPC1L1Cholesterol 7 alpha-hydroxylaseExcretionFecesMiceob/ob03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFenofibrateInternal medicinemedicineAnimalsPPAR alphaTICEATP Binding Cassette Transporter Subfamily G Member 5Liver X receptorMolecular BiologyLiver X ReceptorsSulfonamidesFenofibratebiologyChemistryCholesterolATP Binding Cassette Transporter Subfamily G Member 8Reverse cholesterol transportMembrane Transport ProteinsDrug SynergismCell BiologyGeneral MedicineCholesterol030104 developmental biologyEndocrinology030220 oncology & carcinogenesisABCA1ABCG5/G8biology.proteinIntestinal cholesterol absorptionlipids (amino acids peptides and proteins)medicine.drugMolecular and Cellular Biochemistry
researchProduct

Intestinal cholesterol absorption: identification of different binding proteins for cholesterol and cholesterol absorption inhibitors in the enterocy…

2003

Absorption of cholesterol from the intestine is a central part of body cholesterol homeostasis. The molecular mechanisms of intestinal cholesterol absorption and the proteins mediating membrane transport are not known. We therefore aimed to identify the proteins involved in intestinal cholesterol absorption across the luminal brush border membrane of small intestinal enterocytes. By photoaffinity labeling using photoreactive derivatives of cholesterol and 2-azetidinone cholesterol absorption inhibitors, an 80-kDa and a 145-kDa integral membrane protein were identified as specific binding proteins for cholesterol and cholesterol absorption inhibitors, respectively, in the brush border membra…

MaleBrush bordermedicine.drug_classBiologyCholesterol 7 alpha-hydroxylaseIntestinal absorptionSubstrate SpecificityCholesterol DietaryEzetimibeIntestine SmallmedicineAnimalsTissue DistributionCholesterol absorption inhibitorMolecular BiologyMicrovilliMolecular StructureAnticholesteremic AgentsReverse cholesterol transportMembrane ProteinsBiological TransportCell BiologyMembrane transportMolecular WeightEnterocytesIntestinal AbsorptionBiochemistryIntestinal cholesterol absorptionlipids (amino acids peptides and proteins)RabbitsCarrier Proteinsmedicine.drugBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
researchProduct

Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients

2010

BACKGROUND: Reducing low-density lipoprotein cholesterol (LDL-C) is the primary goal of therapy in patients with hypercholesterolemia and coronary heart disease (CHD). METHODS: This double blind placebo-controlled study enrolled patients 18 to 75 years of age with primary hypercholesterolemia and establishedCHDwhowere taking a stable daily dose of simvastatin 20 mg. Patients were randomized to ezetimibe/simvastatin 10/20 mg (eze/simva; n 5 56) or simvastatin 40 mg (simva; n 5 56) for 6 weeks. Percent change from baseline in LDL-C, total cholesterol, high-density lipoprotein cholesterol (HDL-C), and triglycerides were assessed by use of the Student t test. The percent of patients achieving L…

MaleSimvastatinSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismCoronary DiseasePharmacologyGastroenterologylaw.inventionchemistry.chemical_compoundRandomized controlled triallawCholesterol absorption inhibitorEzetimibe; simvastatin; coronary heart diseaseNutrition and DieteticsAnticholesteremic AgentsMiddle AgedLipidCoronary heart diseaseCholesterolDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular Medicinemedicine.drugAdultmedicine.medical_specialtyAdolescentmedicine.drug_classHypercholesterolemiaPharmacotherapyDouble-Blind MethodEzetimibeInternal medicineInternal MedicinemedicineHumansTriglyceridesCholesterol absorption inhibitorAgedCholesterolbusiness.industryCholesterol HDLCholesterol absorption inhibitor; Coronary heart disease; Ezetimibe; Lipids; SimvastatinCholesterol LDLEzetimibeClinical trialchemistrySimvastatinAzetidinesEzetimibe/simvastatinbusinessJournal of Clinical Lipidology
researchProduct

Cholesterol and saturated fat intake determine the effect of polymorphisms at ABCG5/ABCG8 genes on lipid levels in children.

2006

Purpose: Analysis of mutations in genes of the cholesterol metabolic pathway has not completely explained the interindividual variability of blood cholesterol concentrations attributed to gene–nutrient interactions. Thus, we analyzed polymorphisms in the ABCG5 and ABCG8 genes, involved in the regulation of intestinal cholesterol absorption, with special interest in a potential interaction with diet to determine lipid levels. Methods: The polymorphisms ABCG5 C1950G (Gln604Glu) and ABCG8 C1895T (Ala640Val) were determined by polymerase chain reaction and restriction analysis in 1227 healthy school children, aged 6 to 8 years. Results: No significant differences were found in blood lipid level…

Malemedicine.medical_specialtyApolipoprotein BLipoproteinsBlood lipidsABCG8Cholesterol Dietarychemistry.chemical_compoundGene FrequencyPolymorphism (computer science)Internal medicineSurveys and QuestionnairesGenotypemedicineHumansATP Binding Cassette Transporter Subfamily G Member 5ChildGenetics (clinical)GeneticsPolymorphism GeneticbiologyBase SequenceCholesterolATP Binding Cassette Transporter Subfamily G Member 8DNADietary FatsLipidsEndocrinologychemistryABCG5biology.proteinIntestinal cholesterol absorptionlipids (amino acids peptides and proteins)ATP-Binding Cassette TransportersFemaleGenetics in medicine : official journal of the American College of Medical Genetics
researchProduct

Effect of aqueous extract of Ajuga iva supplementation on plasma lipid profile and tissue antioxidant status in rats fed a high-cholesterol diet

2006

Abstract The present study was designed to explore the possible antioxidant and hypolipidemic effects of the aqueous extract of Ajuga iva (0.5% in the diet) in rats fed a high-cholesterol (1%) diet (HCD). The results indicated that the HCD-Ai versus HCD treatment led to many changes in biochemical parameters. They showed a decrease of plasma total cholesterol (TC) and VLDL-cholesterol but an increase of HDL2-cholesterol. The triacylglycerol contents were reduced in plasma and in VLDL. The lipid peroxidation determined by TBARS was decreased by 75% in plasma. TBARS in liver, heart and kidneys were highly reduced excepted in the adipose tissue. Ajuga iva treatment enhanced superoxide dismutas…

Malemedicine.medical_specialtyVery low-density lipoproteinAntioxidantLipoproteinsmedicine.medical_treatmentHypercholesterolemiaAdipose tissueAjugaThiobarbituric Acid Reactive SubstancesAntioxidantsAjugaCholesterol DietaryLipid peroxidationEatingchemistry.chemical_compoundInternal medicineDrug DiscoverymedicineTBARSAnimalsRats WistarPharmacologybiologyPlant ExtractsCholesterolBody WeightOrgan Sizebiology.organism_classificationLipidsDietEnzymesRatsEndocrinologychemistryDietary SupplementsIntestinal cholesterol absorptionlipids (amino acids peptides and proteins)Journal of Ethnopharmacology
researchProduct

Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia.

2010

Ezetimibe is a selective cholesterol absorption inhibitor with an excellent side-effect profile, able to reduce low-density lipoprotein (LDL) cholesterol by 15-25% from baseline in monotherapy and on top of statins and fibrates. Yet, it seems that ezetimibe produces quantitative rather than qualitative changes in LDL, with small net effects on atherogenic dyslipidaemia. This is supported by findings from the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) study on atherosclerosis progression, where the addition of ezetimibe to simvastatin in patients with heterozygous familial hypercholesterolaemia did not affect the mean change in carotid int…

cardiovascular riskAortic valvemedicine.medical_specialtydyslipidaemiamedicine.drug_classezetimibe cardiovascular risk atherosclerosis dyslipidaemiachemistry.chemical_compoundEzetimibeInternal medicineClinical endpointMedicineCholesterol absorption inhibitorcardiovascular diseasesReview Paperbusiness.industryCholesterolnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseStenosismedicine.anatomical_structureEndocrinologychemistrySimvastatinCardiologylipids (amino acids peptides and proteins)atherosclerosisbusinessezetimibeLipoproteinmedicine.drug
researchProduct

Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients.

2007

Increasing evidence suggests that the quality-rather than just the quantity-of low-density lipoproteins (LDLs) exerts a great influence on cardiovascular risk. LDLs comprise multiple subclasses with discrete size and density, and different physicochemical composition, metabolic behaviors, and atherogenicity. Individuals generally cluster into 2 broad subgroups. Most have a predominance of large LDLs, and some have a higher proportion of small particles. Small, dense LDLs are good predictors of cardiovascular events and progression of coronary artery disease. Their predominance has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Tre…

cardiovascular riskRiskStatinmedicine.drug_classHypercholesterolemiasubclassePharmacologyBioinformaticschemistry.chemical_compoundClofibric AcidEzetimibemedicineHumansPharmacology (medical)Cholesterol absorption inhibitorRosuvastatinRisk factorRosuvastatin CalciumNational Cholesterol Education ProgramSulfonamidessmall dense LDLfibrateCholesterolbusiness.industryAnticholesteremic AgentsstatinGeneral MedicineCholesterol LDLEzetimibeFluorobenzenesRosuvastatin CalciumPyrimidineschemistrydiabeteCardiovascular DiseasesAzetidineslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorsbusinessrosuvastatinmedicine.drugAdvances in therapy
researchProduct

Role of Nutraceuticals in Hypolipidemic Therapy.

2015

Nutraceuticals are food components or active ingredients present in foods and used in therapy. This article analyzes the characteristics of the molecules with a lipid-lowering effect. The different nutraceuticals may have different mechanisms of action: inhibition of cholesterol synthesis primarily through action on the enzyme HMG-CoA reductase (policosanol, polyphenols, garlic and, above all, red yeast rice), increase in LDL receptor activity (berberine), reduction of intestinal cholesterol absorption (garlic, plant sterols, probiotics), and also the ability to interfere with bile metabolism (probiotics, guggul). Based on the different mechanisms of action, some nutraceuticals are then abl…

lcsh:Diseases of the circulatory (Cardiovascular) systemSettore MED/09 - Medicina InternaCombination therapyPharmacologyCardiovascular Medicinelipidschemistry.chemical_compoundNutraceuticalBerberinelipidRed yeast riceReviews in MedicineMedicineLDL-cholesterolPolicosanolActive ingredientnutraceuticalsbusiness.industrycardiovascular preventionClinical trialchemistrylcsh:RC666-701Intestinal cholesterol absorptionhypolipidemic therapynutraceuticalCardiology and Cardiovascular Medicinebusinessmedicine.drugFrontiers in cardiovascular medicine
researchProduct